Metabolomic study of human tissue and urine in clear cell renal carcinoma by LC-HRMS and PLS-DA

被引:0
作者
Joanna Nizioł
Vincent Bonifay
Krzysztof Ossoliński
Tadeusz Ossoliński
Anna Ossolińska
Jan Sunner
Iwona Beech
Adrian Arendowski
Tomasz Ruman
机构
[1] Rzeszow University of Technology,Faculty of Chemistry
[2] University of Oklahoma,Department of Microbiology and Plant Biology
[3] John Paul II Hospital,Department of General Surgery and Urology
[4] Montana State University,Department of Chemistry
[5] Montana State University,Center of Biofilm Engineering
来源
Analytical and Bioanalytical Chemistry | 2018年 / 410卷
关键词
Renal cell carcinoma; Mass spectrometry; Biomarker; Cancer biomarker; Kidney;
D O I
暂无
中图分类号
学科分类号
摘要
Renal cell carcinoma (RCC) is the most prevalent and lethal malignancy of the kidney. Despite all the efforts made, no tissue biomarker is currently used in the clinical management of patients with kidney cancer. A search for possible biomarkers in urine for clear cell renal cell carcinoma (ccRCC) has been conducted. Non-targeted metabolomic analyses were performed on paired samples of surgically removed renal cancer and normal tissue, as well as on urine samples. Extracts were analyzed by liquid chromatography/high-resolution mass spectrometry (LC-HRMS). Hydroxybutyrylcarnitine, decanoylcarnitine, propanoylcarnitine, carnitine, dodecanoylcarnitine, and norepinephrine sulfate were found in much higher concentrations in both cancer tissues (compared with the paired normal tissue) and in urine of cancer patients (compared with control urine). In contrast, riboflavin and acetylaspartylglutamate (NAAG) were present at significantly higher concentrations both in normal kidney tissue as well as in urine samples of healthy persons. This preliminary study resulted in the identification of several compounds that may be considered potential clear cell renal carcinoma biomarkers.
引用
收藏
页码:3859 / 3869
页数:10
相关论文
共 407 条
[1]  
Johnson CH(2016)Metabolomics: beyond biomarkers and towards mechanisms Nat Rev Mol Cell Biol 17 451-459
[2]  
Ivanisevic J(2011)Regulation of cancer cell metabolism Nat Rev Cancer 11 85−95-105
[3]  
Siuzdak G(2016)The 2016 WHO classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours Eur Urol 70 93-624
[4]  
Cairns RA(2015)Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity Eur Urol 67 85−97-2172
[5]  
Harris IS(2003)Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma Am J Surg Pathol 27 612-75
[6]  
Mak TW(2003)The genetic basis of cancer of the kidney J Urol 170 2163-238
[7]  
Moch H(2003)Immunotherapy for renal cell carcinoma Eur Urol 44 65-203
[8]  
Cubilla AL(2008)Current insights in renal cell cancer pathology Urol Oncol 26 225-2374
[9]  
Humphrey PA(2001)Renal cell carcinoma Curr Opin Oncol 13 199-75
[10]  
Reuter VE(2015)NMR metabolomics of renal cancer: an overview Bioanalysis 7 2361-865